Co-expression of Epstein-Barr virus latent membrane protein and vimentin in "aggressive" histological subtypes of Hodgkin's disease
- PMID: 7679848
- DOI: 10.1007/BF01605131
Co-expression of Epstein-Barr virus latent membrane protein and vimentin in "aggressive" histological subtypes of Hodgkin's disease
Abstract
The presence of Epstein-Barr virus (EBV) genome in Hodgkin's and Reed-Sternberg (HRS) cells, as detected using in situ hybridization (ISH) with biotinylated BamHI "V" probes, along with the expression of EBV-encoded latent membrane protein (LMP) and vimentin was examined in paraffin-embedded sections of 39 immunomorphologically characterized cases of Hodgkin's disease (HD). ISH demonstrated EBV in HRS cells in 15 of 39 cases, whereas LMP expression was detected in 11 of 39 cases, only in the presence of EBV genome detection. With the exception of 1 case, in which HRS cells expressed B-cell-associated antigens, the LMP-positive cases included specimens in which HRS cells were of non-B, non-T phenotype. LMP expression showed a stronger association with lymphocyte depletion (LD) (3/3) and mixed cellularity (MC) (6/11) than with lymphocyte predominance (0/5) or nodular sclerosis (2/20) subtypes. Vimentin expression on HRS cells was found in all the LMP-expressing cases and only in a fraction (13/28) of LMP-negative cases. This study supports the view that HD represents a heterogeneous group of diseases also in terms of EBV association, LMP expression being strongly related to the "aggressive" LD and MC histological subtypes. In light of the supposed interactions between vimentin and LMP, their co-expression on HRS cells, as detected in this study, provides further evidence for a significant role of EBV in the development of a proportion of HD cases.
Similar articles
-
Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency.Hum Pathol. 1993 Jul;24(7):725-9. doi: 10.1016/0046-8177(93)90008-5. Hum Pathol. 1993. PMID: 8100553
-
Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease.Am J Pathol. 1992 Feb;140(2):247-53. Am J Pathol. 1992. PMID: 1310829 Free PMC article.
-
Expression of the Epstein-Barr virus encoded latent membrane protein in tumor cells of Hodgkin's disease occurring in childhood.Acta Morphol Hung. 1992;40(1-4):223-30. Acta Morphol Hung. 1992. PMID: 1365766
-
Immunohistochemical detection of Epstein-Barr virus-encoded latent membrane protein in Reed-Sternberg cells and variants of Hodgkin's disease.Mod Pathol. 1994 May;7(4):454-61. Mod Pathol. 1994. PMID: 7520586 Review.
-
Significance of the detection of Epstein-Barr virus DNA in lymph nodes in patients with Hodgkin's disease.Leuk Lymphoma. 1992 Nov;8(4-5):319-25. doi: 10.3109/10428199209051010. Leuk Lymphoma. 1992. PMID: 1337849 Review.
Cited by
-
Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.Adv Hematol. 2011;2011:439456. doi: 10.1155/2011/439456. Epub 2011 Jan 18. Adv Hematol. 2011. PMID: 21318045 Free PMC article.
-
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482239 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials